

1 **Personalized CZA-ATM dosing against an XDR *E. coli* in liver transplant**
2 **patients; the application of the *in vitro* hollow fibre infection model**
3 **(HFIM)**

4 Zahra Sadouki^{1, 2, [□]}, Emmanuel Q. Wey^{2, 3, [□]}, Sateesh Iype⁴, David Nasralla⁴, Jonathan Potts⁵,
5 Mike Spiro^{6,7}, Alan Williams⁸, Timothy D. McHugh², Frank Kloprogge¹

6 1 Institute for Global Health, University College London, UK

7 2 Centre of Clinical Microbiology, University College London, UK

8 3 Department of Infection, Royal Free London NHS Trust, UK

9 4 Department of HPB and Liver Transplant Surgery Royal Free Hospital

10 5 Department of Hepatology, Sheila Sherlock Liver Unit, Royal Free London

11 6 Department of Surgical biotechnology, UCL

12 7 Department of Intensive care medicine Royal Free London

13 8 Department of Infection Sciences, Health Services Laboratories, London, UK,

14

15 [□] Both authors contributed equally

16 **Corresponding author:** Dr Emmanuel Wey, Department of Infection, Consultant and Honorary Associate
17 Professor in Infection, Royal Free London NHS Trust, Centre for Clinical Microbiology, Division of
18 Infection & Immunity, University College London

19 emmanuel.vey@nhs.net

20 **Keywords:** XDR *Escherichia coli*, Ceftazidime-Avibactam, Aztreonam, personalised medicine, hollow fibre
21 infection model

22 **Electronic word count:** 2193 (excluding reference list)

23 **Number of figures:** One main figure, one supplementary figure

24 **Number of tables:** Three supplementary tables

25 **Conflict of interest statement:** No conflicts of interest.

26 **Financial support statement:** This work was conducted as part of Z.S.'s PhD studentship that was
27 partially funded by an educational grant from Shionogi B.V. and by University College London. FK has
28 been recipient of a UKRI Medical Research Council Skills Development Fellowship MR/P014534/1, and a
29 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number
30 220587/Z/20/Z).

31 **Authors contribution statement:** All authors contributed to the inception and planning of the work. ZS[□]
32 and EW[□] wrote the manuscript and contributed equally, and all authors edited.

33 **Abstract**

34 **Background & aims:** An extensively-drug resistant (XDR) NDM and OXA-48 producing *E. coli* contributing
35 to repeat episodes of biliary sepsis was isolated from the blood stream of a 45-55 year-old male with a
36 background of IgG4 related sclerosing cholangitis. The patient was awaiting orthotopic liver transplant
37 (OLT). There is no standardized antibiotic prophylaxis regimen however in line with the Infectious
38 Diseases Society of America (IDSA) guidance an antibiotic prophylactic regimen of Ceftazidime-
39 Avibactam (CZA) 2.5g TDS with Aztreonam (ATM) 2g TDS IV was proposed.

40 **Methods:** To inform the individualised pharmacodynamic outcome likelihood prior to prophylaxis dosing
41 the hollow fibre infection model (HFIM) was applied to simulate the *in vivo* antibiotic exposures of the
42 CZA-ATM regimen. The HFIM was inoculated with $\sim 10 \times 10^5$ bacterial CFU/mL of the XDR *E. coli* strain
43 and CFUs/mL were measured for a total of 120 hours to determine the *in vitro* PK/PD killing dynamics.

44 **Results:** A 4-log reduction in CFU/mL in the first ten hours of the regimen exposure was observed
45 however the killing dynamics were slow and six eight-hourly infusions were required to reduce bacterial
46 cells to below the limit of quantification. Thus, the HFIM supported the use of the regimen for infection
47 clearance however highlighted the need for several infusions. Standard local practise is to administer
48 prophylaxis antibiotics at induction of OLT however the HFIM provided data to rationalise earlier dosing
49 therefore the patient was dosed at 24 hours prior to their OLT induction. The patient was subsequently
50 discharged 8 days after surgery.

51 **Conclusions:** The HFIM provides a dynamic culture solution for informing individualised medicine by
52 testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient's
53 infection.

54 **Introduction**

55 Antibiotic prophylaxis in the perioperative period is the standard of care and routinely prescribed during
56 surgical procedures including solid organ transplantation (SOT). Although evidence suggests an overall
57 benefit in reducing postoperative infections the standard of care regimen and duration vary between
58 transplant centres¹⁻³. Here we present the application of the Hollow Fibre Infection Model (HFIM) to
59 inform perioperative personalised antimicrobial dosing in a complex clinical setting. It is anticipated that
60 antimicrobial combination therapy will require case-by-case based selection, accounting for individual
61 risk factors and local patterns of resistance, given the rising incidence of multi drug resistant infections
62 in solid organ transplant donors and recipients. Systematic reviews and meta-regression analysis has
63 indicated that there is statistically significant risk associated with gastrointestinal-tract colonisation of
64 carbapenem resistant enterobacterales (CRE) and subsequent infection with CRE⁴. Informing
65 personalised dosing requires *in vitro* testing beyond MIC reporting which for XDR and PDR infections
66 only serves to highlight the limited options of antimicrobials⁵. In these contexts, HFIM provides an *in*
67 *vitro* tool which can inform perioperative dosing. The semi permeable hollow fibres retain the bacteria
68 in the extra capillary space (ECS) whilst allowing for flow of nutrients and drugs. Therefore, the bacteria
69 isolated from the patient can be challenged against dynamic *in vivo* mimicking antimicrobial exposures
70 to investigate bacterial PD⁶.

71 **Materials/Patients and methods**

72 **Information on clinical findings and diagnostic assessment**

73 An inpatient 45-55 year-old male at University College London Hospitals NHS Foundation Trust (UCLH),
74 also under the care of Hepatology and Hepatobiliary surgery teams at Royal Free London NHS
75 Foundation Trust (RFL), previously diagnosed with IgG related sclerosing cholangitis⁴ presented with
76 recurrent biliary sepsis over a three-month period. Source control of the infections was not achieved by
77 empirical antibiotic treatment due to the presence of three metallic stents in his biliary tree and an
78 internalised percutaneous biliary drain. Blood culture samples and testing of the perihepatic collection
79 fluid confirmed several MDR NDM, and OXA-48 positive gram-negative bacterial strains (Supplementary
80 Table 3) with a combined resistance across nine major antibiotic classes. Further complicating the
81 patient's clinical management was the damage to the liver and loss of synthetic function therefore at
82 the time the patient was placed on the NHS waiting list for orthotopic liver transplantation (OLT). The
83 Infectious Diseases Society of America (IDSA) guidance on the treatment of antimicrobial-resistant gram-

84 negative infections particularly MBL-producing CRE (e.g., NDM, IMP, VIM) suggests intravenous three
85 times daily dosing of 2.5g Ceftazidime-Avibactam (CZA) in addition to 2g aztreonam (ATM)⁷. In addition,
86 several clinical infectious disease publications report efficacy of CZA plus ATM in patients with BSIs⁸⁻¹⁰.
87 Further antibiotic susceptibility testing (AST) revealed CZA-ATM synergy where ATM activity was
88 restored when in combination with AVI (Supplementary Table 1). Therefore, the HFIM was employed as
89 a proof of concept to simulate the *in vivo* dynamic concentrations of the proposed treatment of a three-
90 way antibiotic dosing regimen to be administered to a clinically complex patient.

91 **Laboratory consumables and experimental setup**

92 The laboratory control strain (ATCC 25922[®]) and the clinical isolate (XDR *E. coli*) were prepared
93 identically. Each were cultured at 37°C in ambient air on nutrient agar and cryopreserved in Microbank™
94 beads at -80°C. MICs were determined following CLSI guidelines for microbroth dilution¹¹. A mid-log
95 phase inoculum for each isolate was prepared for the HFIM by refreshing a fresh overnight culture
96 incubated in a shaking incubator at 200 rpm and 37°C in cation adjusted Mueller Hinton broth (CAMHB;
97 Sigma, UK). A 1:50 dilution from this culture was performed to inoculate the HFIM ECS, achieving a final
98 bacterial load of 10⁵ CFU/mL in the ECS.

99 The R-Shiny web application promoted by The International Society of Anti-Infective Pharmacology
100 (ISAP) and ESCMID PK/PD of anti-infectives study group (EPASG) was used to define experimental setup
101 parameters¹². The following C_{max} concentrations were mimicked; CAZ 80 µg/L, AVI 14 µg/L, ATM 120
102 µg/L. A T_½ of 2.48 hours was simulated in the HFIM. Antibiotic powders were dissolved in solvents
103 recommended by the manufacturers (CAZ; Sigma, AVI; MCE and ATM; TOKU-E).

104 CAMHB (Sigma; UK) was broth media used in the HFIM system. The hollow fibre cartridge was sourced
105 from FibreCell systems (High flux PS, C2011). The FibreCell duet pump was set at 100 mL/min to allow
106 the cartridge and central reservoir to reach equilibrium. A peristaltic pump (Minipuls evolution®, Gilson)
107 was set at 0.699 mL/min to mimic T_½ of 2.48. The syringe driver pumps (AL-1000, WPI) were
108 programmed to automatically dose 2 mL infusions every 8 hours over 2 hours and 1 hour respectively
109 for CZA and ATM, administration was concurrent and direct into the central reservoir. Dosing timepoints
110 were at 0, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, 104 and 112.

111 The cartridge ECS was sampled on Mueller Hinton agar (MHA) (VWR; UK) to quantify CFUs as well as on
112 colombia blood agar (VWR; UK) to confirm the absence of contamination. The experiment with the
113 laboratory control strain (ATCC 25922[®]) and the clinical isolate (XDR *E. coli*) were both performed in

114 biological duplicate and all bacterial CFU/mL measurements were performed in technical duplicates at
115 timepoints 0, 2, 4, 6, 8, 10 to capture the initial killing dynamics then again, every 24 hours for five days
116 to capture sustained killing or re-growth.

117 **Results**

118 MICs demonstrated synergy between ATM-AVI against the XDR *E. coli* isolated from the patients' blood
119 stream. MICs were as follows CAZ; >80, AVI; >14, ATM; >120, CZA; >32/4, ATM-AVI; 2/4 and CZA-ATM;
120 2.5/0.44/3.8. Although CLSI and EUCAST are yet to establish breakpoints for the ATM-AVI combination,
121 this MIC and synergy data seen fell within range of previous *in vitro* studies reporting MICs between
122 $\leq 0.03/4$ and $8/4$ $\mu\text{g/mL}$, most typically $\leq 2/4$ $\mu\text{g/mL}$ for MBL-producing Enterobacterales^{13,14} .

123 The XDR *E. coli* challenged with CZA-ATM combination therapy infusions produced a steady rate of
124 killing for the first 10 hours with a 4-log reduction in bacterial CFU/mL however six eight-hourly infusions
125 were required to reduce bacterial cells to below the limit of quantification (Figure 1). Therefore, multiple
126 infusions were required to achieve bacterial source control. The HFIM data demonstrated the proposed
127 combination therapy was only effective at clearing the XDR *E. coli* after two days of administration of
128 eight hourly infusions. Thus, this suggests longer extended infusions or earlier administration of
129 prophylaxis would be necessary for this patient as towards the end of the infusion the simulated
130 concentration of both ATM and CAZ drop below their respective MICs.

131 In general clamping of the inferior vena cava occurs at two to three hours after induction followed by
132 anhepatic period from three to four hours post induction of the OLT during which the mobilisation and
133 explantation of the native Liver takes place. It would be at this point when and mobilisation and removal
134 of the primary prosthetic sources of XDR biofilm would take place. Surgical implantation of the new
135 deceased donor graft would therefore theoretically coincide with the MIC nadir and potential
136 bacteraemia resulting from explantation of the native liver and if the first dose were given at induction it
137 would also coincide a CFU/mL load above the LOD. This informed the patients antibiotic prophylaxis ,
138 and Ceftazidime avibactam 2.5g iv and Aztreonam 2g IV were first dosed at 12 hours prior to the
139 anhepatic phase of their OLT induction thus different to the standard local practise of administering
140 prophylaxis antibiotics at induction of OLT 8-hoturly for a total period of 48 hours. The patient received
141 a DCD graft with side-to-side piggyback anastomosis and portal vein end-to-end anastomosis and Roux-
142 en-Y Hepaticojejunostomy with removal of a previously internalised percutaneous biliary drain.

143 The patient was discharged 8 days after surgery and had no reoccurrence of XDR *E. coli* infection
144 reported in the year after follow up. Incidentally, the patient has also remained CRE negative on
145 screening post OLT.

146 **Conclusions**

147 Several attempts have been made to develop *in vitro* laboratory susceptibility testing methods for the
148 combination of CZA with ATM against XDR GNB¹⁵⁻¹⁷. However, these methods test static antibiotic
149 concentrations. Here we challenged a patient XDR BSI isolate against dynamic *in vivo* simulated
150 concentrations of the CZA-ATM antibiotic combination. The HFIM data demonstrated the CZA-ATM
151 antibiotic regimen was effective at clearing the bacterial cells below the limit of detection in the hollow
152 fibre ECS however multiple infusions were required. The Royal Free London Trust standard of care is to
153 administer prophylactic antibiotics for orthotopic liver transplant (OLT) at induction³. However, the slow
154 killing dynamics observed in the HFIM provided *in vitro* evidence to support prophylactic administration
155 prior to OLT as well as an extended prophylactic duration of 48-hours. Therefore, the patient awaiting a
156 liver transplant was dosed 12 hours earlier than standard local practice. The patient was subsequently
157 discharged 8 days after OLT. The unpredictability relating to the timing and lead times associated with
158 deceased donor grafts offers complicates the practicality of commencing antibiotic prophylaxis in this
159 patient cohort far in advance of 12 hours. This is compounded by the requirement to administer both
160 ceftazidime-avibactam and aztreonam concomitantly.

161 The increased application of alternative synergistic combinations of antibiotic agents necessitates
162 improved methodologies and approaches of *in vitro* evaluation of combination regimens. We
163 demonstrate extended prophylaxis periods are superior for a chronically infected patient where source
164 control has not been achieved with conventional antibiotic treatment and alternative combination
165 regimens are used. The need of standardized methods to support personalised medicine will be
166 increased as the antibiotic resistance era heightens. The HFIM provides a solution to testing different
167 antibiotic regimens against the exact bacterial isolate cultured from the patient. Specific PK
168 concentration profile of the proposed antibiotics can be mimicked. The increased prescribing of
169 alternative synergistic combinations necessitates improved *in vitro* methodology for evaluating
170 personalized dosing. The HFIM provides a dynamic culture solution for testing personalized antibiotic
171 regimens and exposures against the bacterial isolates cultured from the patient. This could inform
172 targeting therapy which could preserve antimicrobials and uphold antimicrobial stewardship.

173 **Informed consent**

174 The patient was consented for Orthotopic liver transplantation and normothermic perfusion as is
175 standard for all patients and includes consent for Research publications of outcomes and the use of
176 peri-transplant tissue samples for research. In this case no patient or deceased donor tissue was used in
177 vitro testing.

178 **References**

- 179 1. Anesi, J. A., Blumberg, E. A. & Abbo, L. M. Perioperative Antibiotic Prophylaxis to Prevent
180 Surgical Site Infections in Solid Organ Transplantation. *Transplantation* **102**, 21–34 (2018).
- 181 2. Abbo, L. M. & Grossi, P. A. Surgical site infections: Guidelines from the American Society
182 of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* **33**, (2019).
- 183 3. Campos-Varela, I. *et al.* What is the optimal antimicrobial prophylaxis to prevent
184 postoperative infectious complications after liver transplantation? A systematic review of
185 the literature and expert panel recommendations. *Clin Transplant* **36**, e14631 (2022).
- 186 4. Willems, R. P. J. *et al.* Incidence of infection with multidrug-resistant Gram-negative
187 bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-
188 regression analysis. *Lancet Infect Dis* **23**, 719–731 (2023).
- 189 5. Gajic, I. *et al.* Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently
190 Used Methods. *Antibiotics* **11**, (2022).
- 191 6. Sadouki, Z. *et al.* Application of the hollow fibre infection model (HFIM) in antimicrobial
192 development: a systematic review and recommendations of reporting.
193 doi:10.1093/jac/dkab160.
- 194 7. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections:
195 Version 1.0. <https://www.idsociety.org/practice-guideline/amr-guidance/>.
- 196 8. Falcone, M. *et al.* Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
197 Bloodstream Infections Caused by Metallo- β -lactamase-Producing Enterobacterales.
198 *Clinical Infectious Diseases* **72**, 1871–1878 (2021).

- 199 9. Yasmin, M. *et al.* Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the
200 Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp.
201 Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo- β -
202 Lactamase-1. *Clin Infect Dis* **71**, 1095 (2020).
- 203 10. Falcone, M. *et al.* Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With
204 Bloodstream Infections Caused by Metallo- β -lactamase-Producing Enterobacterales.
205 *Clinical Infectious Diseases* **72**, 1871–1878 (2021).
- 206 11. CLSI. *M100 | Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition.*
207 (2023).
- 208 12. HF-App. https://varacli.shinyapps.io/hollow_fiber_app/.
- 209 13. Lutgring, J. D. *et al.* Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected
210 in the United States in 2017 and 2018. *Antimicrob Agents Chemother* **64**, (2020).
- 211 14. Chauzy, A. *et al.* Pharmacodynamic modelling of β -lactam/ β -lactamase inhibitor
212 checkerboard data: illustration with aztreonam-avibactam. *Clinical Microbiology and*
213 *Infection* **25**, 515–516 (2019).
- 214 15. Rawson, T. M. *et al.* A practical laboratory method to determine ceftazidime-avibactam-
215 aztreonam synergy in patients with New Delhi metallo-beta-lactamase (NDM)-producing
216 Enterobacterales infection. *J Glob Antimicrob Resist* **29**, 558–562 (2022).
- 217 16. Sreenivasan, P. *et al.* In-vitro susceptibility testing methods for the combination of
218 ceftazidime-avibactam with aztreonam in metallo-beta-lactamase producing organisms:
219 Role of combination drugs in antibiotic resistance era. *The Journal of Antibiotics* 2022 **75**:8
220 **75**, 454–462 (2022).
- 221 17. Khan, A. *et al.* Evaluation of susceptibility testing methods for aztreonam and ceftazidime-
222 avibactam combination therapy on extensively drug-resistant gram-negative organisms.
223 *Antimicrob Agents Chemother* **65**, (2021).

224

225




Figure 1. XDR *E. coli* against Ceftazidime/Avibactam/Aztreonam combination regimen in HFIM. Total bacterial population counts in CFU/mL over time. Data points for XDR *E. coli* (red) represent the geometric mean \pm SD of biological duplicates. Antibiotic infusions were dosed every 8 hours (shown in black at the top of the graph). The lower LOD for quantifying the bacteria was 10 CFU/mL, shown as black dashed line.